Company: TBPH
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001558370-25-011408
Chunk: 6

Company: Theravance Biopharma, Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part II, Item 6E
Chunk 6
---
ITEM 6.   EXHIBITS

​

​​​​​​Incorporated by ReferenceExhibitNumber    Exhibit Description    Filed Herewith    Form    FilingDate/PeriodEnd Date​​​​​​​​​2.1​Assignment Agreement, dated May 30, 2025, by and between Theravance Biopharma, Inc. and GlaxoSmithKline Intellectual Property Development Limited, a private company limited by shares registered under the laws of England and Wales, and, solely with respect to Section 16, Glaxo Group Limited, a private company limited by shares registered under the laws of England and Wales​​​​8-K​June 2, 202531.1​Certification of Chief Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) promulgated pursuant to the Securities Exchange Act of 1934, as amended​X​​​​​​​​​​​​​31.2​Certification of Chief Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) promulgated pursuant to the Securities Exchange Act of 1934, as amended​X​​​​​​​​​​​​​32(1)​Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002​X​​​​​​​​​​​​​101​Financial statements from the quarterly report on Form 10-Q of the Company for the quarter ended June 30, 2025, formatted in iXBRL: (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss), (iii) Condensed Consolidated Statements of Shareholders’ Equity, (iv) the Condensed Consolidated Statements of Cash Flows, and (v) the Notes to the Condensed Consolidated Financial Statements​X​​​​​​​​​​​​​104​Cover Page Interactive Data File (Formatted in iXBRL and contained in Exhibit 101)​X​​​​

(1)The certifications provided as Exhibit 32 are being furnished to accompany the Report pursuant to 18 U.S.C. Section 1350 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of